WRAL

For Women With Early Breast Cancer, Herceptin Treatment Can Be Much Shorter

During the past 20 years, hundreds of thousands of women with breast cancer have taken the drug Herceptin, typically for a year or more. The medicine, used to treat an aggressive form of the disease, ...
Business Wire

Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III ...
Business Wire

Genentech’s Kadcyla Cut the Risk of Disease Recurring by Half Compared to Herceptin in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant ...

– At three years, 88.3 percent of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0 percent treated with ...
Cure Today

TILs May Predict Survival in Early HER2-Positive Breast Cancer Treated With Herceptin

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment. High tumor infiltrating lymphocytes (TILs) in ...
The American Journal of Managed Care

Biosimilar Competition to Herceptin Helped Reduce Price of All Forms of Trastuzumab

A recent study provided new evidence about the effect that the entry of biosimilars has on lowering the price of cancer treatments covered by Medicare. The study, published in the Journal of Clinical ...
Drug Store News

Accord BioPharma get FDA OK for Herceptin biosimilar

Shanghai Henlius Biotech’s partner, Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, has received permission from the Food and Drug Administration for Hercessi (HLX02, ...
Cure Today

FDA Approves Tukysa Plus Herceptin for HER2-Positive Metastatic Colorectal Cancer

The Food and Drug Administration (FDA) approved Tukysa (tucatinib) plus Herceptin (trastuzumab) for the treatment of patients with previously treated HER2-positive metastatic colorectal cancer, ...
Reuters

Pfizer's Herceptin biosimilar succeeds in key breast cancer study

Nov 30 (Reuters) - Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin met the main goal in a key study. Pfizer tested the ...
Reuters

Roche says Herceptin with Pertuzumab "impressive"

ZURICH (Reuters) - Roche Holding AG's Herceptin combined with Pertuzumab showed "impressive results" in a Phase II breast cancer trial, the Swiss drugmaker said on Friday. For the Roche statement, ...
Medscape

Homophilic Antibodies as Immunotherapeutics

Using human tumors in nude mice, the so-called xenograft experiment, showed a significant suppression of the human tumor (Figure 12). The growth of human tumor was delayed and suppressed by homophilic ...